Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A synthetic heptapeptide analog of ACTH(4-10) developed in Russia, where it has been used clinically for decades to treat cerebral ischemia and cognitive impairment. Growing interest in the West for nootropic and neuroprotective applications.
A mixture of low-molecular-weight neuropeptides and amino acids derived from purified pig brain proteins. Approved as a drug in over 50 countries (including much of Europe and Asia) for stroke, traumatic brain injury, and Alzheimer's disease. One of the most clinically studied neuropeptide preparations in the world.
Activates BDNF (brain-derived neurotrophic factor) and its receptor TrkB, promoting neuronal survival, synaptic plasticity, and cognitive function. Also modulates serotonergic, dopaminergic, and adrenergic systems. Reduces oxidative stress and neuroinflammation.
Acts as a neurotrophic factor, mimicking the effects of BDNF, NGF, and other endogenous growth factors. Promotes neuronal survival, synaptic plasticity, and neurogenesis. Reduces excitotoxicity and oxidative stress in neural tissue. Crosses the blood-brain barrier due to its small molecular weight.
- Cognitive enhancement and focus
- Neuroprotection after stroke or ischemia
- Anxiety and depression support
- ADHD symptom management
- Memory and learning improvement
- Stroke recovery and rehabilitation
- Traumatic brain injury recovery
- Alzheimer's disease (approved in some countries)
- Cognitive enhancement
- Neuroprotection
- Limited Western clinical trial data
- Nasal spray form may cause irritation
- Potential stimulant-like effects
- Headaches reported
- Long-term safety profile unknown in Western populations
- Derived from porcine brain — religious/ethical considerations for some
- Injection site reactions
- Rare allergic reactions
- Seizure risk at high doses (rare)
- Not FDA-approved — quality of gray-market sources varies significantly
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026. Has extensive clinical use in Russia for cerebral ischemia and trigeminal neuralgia, but limited US clinical trial data. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
Not FDA-approved in the United States. Approved as a prescription drug in 50+ countries including Germany, Austria, Russia, China, and most of Eastern Europe and Asia. Available in the US only as a research chemical or through international sources. Has the most robust clinical evidence base of any compound in the nootropic peptide category.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.